Real-time enrollment status for this triple negative breast cancer clinical trial
Current Status
Recruiting
Checked: July 18, 2026 at 2:34 AM UTC
| NCT Number | NCT06393374 |
| Recruiting Status | Recruiting |
| Condition | Triple Negative Breast Cancer |
| Phase | PHASE3 |
| Target Enrollment | 1,530 participants |
| Active Locations | 89 sites in the US |
| Sponsor | Merck Sharp & Dohme LLC |
| Last Updated on CT.gov | June 29, 2026 (2 weeks ago) |
As of July 18, 2026: Clinical trial NCT06393374 is currently recruiting participants. This phase3 study for triple negative breast cancer is actively seeking new participants at 89 locations across the United States. The study is sponsored by Merck Sharp & Dohme LLC. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06393374 is actively recruiting participants as of July 18, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 89 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06393374 was last updated 2 weeks ago (June 29, 2026). HelloStudys verifies this status automatically.